Skip to main content

Advertisement

Log in

Myeloid progenitors with PTPN11 and nonRAS pathway gene mutations are refractory to treatment with 6-mercaptopurine in juvenile myelomonocytic leukemia

  • Letter to the Editor
  • Published:
Leukemia Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Figure 1

References

  1. Koike K, Matsuda K . Recent advances in the pathogenesis and management of juvenile myelomonocytic leukaemia. Br J Haematol 2008; 141: 567–575.

    Article  CAS  PubMed  Google Scholar 

  2. Loh ML . Recent advances in the pathogenesis and treatment of juvenile myelomonocytic leukaemia. Br J Haematol 2011; 152: 677–687.

    Article  CAS  PubMed  Google Scholar 

  3. Sakaguchi H, Okuno Y, Muramatsu H, Yoshida K, Shiraishi Y, Takahashi M et al. Exome sequencing identifies secondary mutations of SETBP1 and JAK3 in juvenile myelomonocytic leukemia. Nat Genet 2013; 45: 937–941.

    Article  CAS  PubMed  Google Scholar 

  4. Piazza R, Valletta S, Winkelmann N, Redaelli S, Spinelli R, Pirola A et al. Recurrent SETBP1 mutations in atypical chronic myeloid leukemia. Nat Genet 2013; 45: 18–24.

    Article  CAS  PubMed  Google Scholar 

  5. Damm F, Itzykson R, Kosmider O, Droin N, Renneville A, Chesnais V et al. SETBP1 mutations in 658 patients with myelodysplastic syndromes, chronic myelomonocytic leukemia and secondary acute myeloid leukemias. Leukemia 2013; 27: 1401–1403.

    Article  CAS  PubMed  Google Scholar 

  6. Makishima H, Yoshida K, Nguyen N, Przychodzen B, Sanada M, Okuno Y et al. Somatic SETBP1 mutations in myeloid malignancies. Nat Genet 2013; 45: 942–946.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Meggendorfer M, Bacher U, Alpermann T, Haferlach C, Kern W, Gambacorti-Passerini C et al. SETBP1 mutations occur in 9% of MDS/MPN and in 4% of MPN cases and are strongly associated with atypical CML, monosomy 7, isochromosome i(17)(q10), ASXL1 and CBL mutations. Leukemia 2013; 27: 1852–1860.

    Article  CAS  PubMed  Google Scholar 

  8. Thol F, Suchanek KJ, Koenecke C, Stadler M, Platzbecker U, Thiede C et al. SETBP1 mutation analysis in 944 patients with MDS and AML. Leukemia 2013; 27: 2072–2075.

    Article  CAS  PubMed  Google Scholar 

  9. Shiba N, Ohki K, Park MJ, Sotomatsu M, Kudo K, Ito E et al. SETBP1 mutations in juvenile myelomonocytic leukaemia and myelodysplastic syndrome but not in paediatric acute myeloid leukaemia. Br J Haematol 2013; 164: 156–159.

    Article  PubMed  Google Scholar 

  10. Matsuda K, Matsuzaki S, Miki J, Hidaka E, Yanagisawa R, Nakazawa Y et al. Chromosomal change during 6-mercaptopurine (6-MP) therapy in juvenile myelomonocytic leukemia: the growth of a 6-MP-refractory clone that already exists at onset. Leukemia 2006; 20: 485–490.

    Article  CAS  PubMed  Google Scholar 

  11. Matsuda K, Nakazawa Y, Sakashita K, Shiohara M, Yamauchi K, Koike K . Acquisition of loss of the wild-type NRAS locus with aggressive disease progression in a patient with juvenile myelomonocytic leukemia and a heterozygous NRAS mutation. Haematologica 2007; 92: 1576–1578.

    Article  CAS  PubMed  Google Scholar 

  12. Tartaglia M, Niemeyer CM, Fragale A, Song X, Buechner J, Jung A et al. Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia. Nat Genet 2003; 34: 148–150.

    Article  CAS  PubMed  Google Scholar 

  13. Kratz CP, Niemeyer CM, Castleberry RP, Cetin M, Bergsträsser E, Emanuel PD et al. The mutational spectrum of PTPN11 in juvenile myelomonocytic leukemia and Noonan syndrome/myeloproliferative disease. Blood 2005; 106: 2183–2185.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Matsuda K, Sakashita K, Taira C, Tanaka-Yanagisawa M, Yanagisawa R, Shiohara M et al. Quantitative assessment of PTPN11 or RAS mutations at the neonatal period and during the clinical course in patients with juvenile myelomonocytic leukaemia. Br J Haematol 2010; 148: 593–599.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank Ms Yumiko Oguchi, Department of Pediatrics, Shinshu University School of Medicine, for her technical support.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to K Koike.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Author Contributions

KK and KM designed and performed the research, collected the samples, analyzed the data and wrote the paper. YN designed the research. CI performed the research. TK, KH, SS, MT, KY, RY, KS and SS collected the samples and analyzed the data. All the authors read and approved the manuscript.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Matsuda, K., Nakazawa, Y., Iwashita, C. et al. Myeloid progenitors with PTPN11 and nonRAS pathway gene mutations are refractory to treatment with 6-mercaptopurine in juvenile myelomonocytic leukemia. Leukemia 28, 1545–1548 (2014). https://doi.org/10.1038/leu.2014.58

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2014.58

  • Springer Nature Limited

This article is cited by

Navigation